Top Page
Shanghai Henlius Biotech, Inc. Class H
(2696)
Shanghai Henlius Biotech, Inc. Class H (2696) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Henlius Biotech, Inc. Class H Business Overview & Revenue Model
Shanghai Henlius Biotech, Inc. Class H Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 5.72B | 5.39B | 3.21B | 1.68B | 587.59M |
| Gross Profit | 4.18B | 3.92B | 2.37B | 1.16B | 405.47M |
| EBITDA | 1.15B | 911.33M | -310.61M | -671.74M | -814.06M |
| Net Income | 820.47M | 546.02M | -695.26M | -984.05M | -1.04B |
Balance Sheet | |||||
| Total Assets | 10.60B | 9.90B | 8.92B | 7.17B | 6.44B |
| Cash, Cash Equivalents and Short-Term Investments | 772.96M | 1.01B | 833.66M | 154.98M | 1.11B |
| Total Debt | 3.65B | 4.09B | 3.68B | 2.62B | 1.83B |
| Total Liabilities | 7.58B | 7.71B | 7.29B | 4.88B | 3.24B |
| Stockholders Equity | 3.01B | 2.19B | 1.64B | 2.30B | 3.20B |
Cash Flow | |||||
| Free Cash Flow | 404.68M | 36.48M | -383.67M | -1.04B | -2.12B |
| Operating Cash Flow | 1.24B | 1.05B | 981.62M | 90.39M | -609.58M |
| Investing Cash Flow | -909.97M | -1.00B | -1.36B | -1.68B | -1.51B |
| Financing Cash Flow | -643.37M | 144.43M | 858.02M | 648.30M | 995.79M |
Shanghai Henlius Biotech, Inc. Class H Technical Analysis
Shanghai Henlius Biotech, Inc. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$42.34B | 47.57 | 27.37% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% | |
| ― | €3.13B | ― | -29.51% | ― | ― | ― | |
61 Neutral | HK$25.26B | ― | -3.06% | ― | 68.88% | 55.64% | |
54 Neutral | HK$45.72B | ― | -16.25% | ― | 44.21% | 46.11% | |
| ― | HK$34.94B | 36.58 | 12.36% | 1.24% | ― | ― | |
48 Neutral | HK$30.67B | ― | -161.12% | ― | -56.94% | -190.36% |
Shanghai Henlius Biotech, Inc. Class H Corporate Events
Shanghai Henlius Biotech, Inc. has issued a clarification announcement regarding the closure of its register of members, specifying the requirements for lodging transfer documents and share certificates for registration by August 26, 2025. This announcement ensures that shareholders are informed of the necessary procedures, potentially impacting shareholder transactions and company operations.
Shanghai Henlius Biotech, Inc. announced that its New Drug Application for HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody injection for treating wet age-related macular degeneration (wAMD), has been accepted by China’s National Medical Products Administration. This development is significant as it marks a step forward in the company’s efforts to provide new treatment options for wAMD, a condition with limited approved treatments in China. The acceptance of the NDA follows successful clinical trials demonstrating the drug’s non-inferiority to existing treatments and its favorable safety profile, potentially positioning Henlius as a key player in the ophthalmic drug market.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on August 29, 2025, to discuss and approve several resolutions. These include the re-appointment and appointment of directors and shareholder representative supervisors, as well as proposed amendments to the Rules of Procedures for the General Meeting, the Board, and the Board of Supervisors. The meeting’s outcomes could impact the company’s governance structure and operational procedures, potentially influencing its strategic direction and stakeholder engagement.
Shanghai Henlius Biotech, Inc. has announced the proposed re-appointment and appointment of directors and supervisors for the fourth session of its board. This includes the re-appointment of several current directors and the introduction of new members, reflecting the company’s strategic focus on maintaining a robust governance structure. The decisions are set to be approved at the upcoming Extraordinary General Meeting (EGM), which underscores the company’s commitment to strong leadership and oversight, potentially impacting its market positioning and stakeholder confidence.
Shanghai Henlius Biotech, Inc. has announced that its anti-PD-L1 antibody-drug conjugate, HLX43, has received approval from the U.S. FDA to begin a phase 1 clinical trial for the treatment of thymic carcinoma. This approval marks a significant step in the company’s efforts to advance its oncology pipeline, with plans to conduct further clinical studies in multiple countries. The approval positions Henlius as a key player in the ADC market, particularly as no ADC targeting PD-L1 has been approved globally yet, potentially enhancing its market presence and offering new treatment options for patients with advanced cancers.
Shanghai Henlius Biotech, Inc. announced the commencement of a Phase 2 clinical study for HLX79, a human sialidase fusion protein, in combination with HANLIKANG, for treating active glomerulonephritis in Mainland China. This study aims to evaluate the safety, tolerability, and efficacy of the combination treatment, potentially enhancing B lymphocyte depletion and benefiting patients with autoimmune diseases. The development of HLX79 is part of a global collaboration with Palleon Pharmaceuticals, with Shanghai Henlius holding exclusive rights in China.
Shanghai Henlius Biotech, Inc. has announced a board meeting scheduled for August 25, 2025, to review and approve the interim results for the first half of 2025 and to discuss the potential payment of an interim dividend. This meeting could influence the company’s financial strategy and shareholder returns, potentially impacting its market position and investor relations.
Shanghai Henlius Biotech, Inc. announced that its biosimilar drug HLX14, a recombinant anti-RANKL human monoclonal antibody injection, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation for approval is a significant step towards gaining centralized marketing authorization across the EU and EEA countries. The positive opinion is based on data demonstrating analytical similarity and clinical efficacy compared to the reference drug, denosumab. This development positions Henlius as a competitive player in the global biosimilar market, with potential implications for stakeholders as the drug progresses towards final approval.
Shanghai Henlius Biotech, Inc. held its 2025 second extraordinary general meeting where several resolutions were passed. These included the approval of a Share Option Scheme and an RSU Scheme, both receiving overwhelming support from shareholders. The meeting was conducted in compliance with relevant laws and regulations, and the resolutions are expected to enhance the company’s operational flexibility and incentivize service providers, potentially strengthening its market position.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in the United States for its international multi-center phase 3 clinical study of HLX22, a recombinant humanized anti-HER2 monoclonal antibody, in combination with Trastuzumab and chemotherapy for the treatment of HER2-positive gastroesophageal junction and gastric cancer. This study, which is also being conducted in China, Australia, Japan, and other regions, aims to evaluate the efficacy and safety of HLX22, potentially enhancing the company’s position in the oncology market by addressing critical unmet needs in cancer treatment.
Shanghai Henlius Biotech, Inc. has announced an extraordinary general meeting to be held on July 21, 2025, to consider and approve several resolutions related to its Share Option Scheme and RSU Scheme. These resolutions include authorizing the issuance of shares and granting RSUs, which could impact the company’s operational flexibility and stakeholder interests.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Biologics, has received EU GMP certification for its production lines of HLX11 and HLX14, indicating compliance with European manufacturing standards. This certification enhances the company’s industry positioning by facilitating the global commercialization of its biosimilar products, potentially impacting stakeholders by expanding market access and increasing competitiveness in the pharmaceutical industry.
Shanghai Henlius Biotech, Inc. has entered into a license agreement with FBD Biologics Limited for the exclusive rights to develop, manufacture, and commercialize the fusion protein HCB101 in specified territories including Mainland China, Hong Kong, Macao, Southeast Asia, and parts of the MENA region. This strategic partnership allows Henlius to advance its oncology pipeline with HCB101, currently in phase 1b/2a clinical trials, potentially enhancing its market positioning and offering significant growth opportunities in the biopharmaceutical sector.
Shanghai Henlius Biotech, Inc. has announced the proposed adoption of a Share Option Scheme and an RSU Scheme, aimed at attracting and retaining skilled personnel to drive the company’s long-term development goals. The schemes, subject to shareholder approval, are designed to align the interests of participants with shareholders through share ownership, and include conditional grants to key personnel, such as Dr. Zhu, to enhance the company’s value and stakeholder benefits.
Shanghai Henlius Biotech, Inc. has announced proposed amendments to its Articles of Association and other corporate governance measures to align with updated legal and regulatory requirements. Additionally, the company has appointed new members to its Nomination Committee, enhancing its governance structure in accordance with revised listing rules.
Shanghai Henlius Biotech, Inc. has announced amendments to the terms of reference for its Nomination Committee, initially established in 2019. The changes emphasize the inclusion of independent non-executive directors and gender diversity within the committee, reflecting the company’s commitment to robust governance and inclusive leadership practices.
Shanghai Henlius Biotech, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the governance structure and strategic oversight, potentially impacting the company’s future direction and market positioning.
Shanghai Henlius Biotech, Inc. announced the dosing of the first patient in a bridging study in Japan for HANSIZHUANG, combined with chemotherapy, targeting extensive-stage small cell lung cancer. This study aims to support the future marketing application of HANSIZHUANG in Japan, following successful international trials. The company is advancing multiple clinical studies globally, enhancing its position in the oncology market.
Shanghai Henlius Biotech, Inc. has announced the dosing of the first patient in an international multicentre phase 2 clinical study of HLX43, an anti-PD-L1 antibody-drug conjugate, for advanced non-small cell lung cancer in mainland China. This study aims to evaluate the efficacy and safety of HLX43, with the primary endpoint being the objective response rate. The phase 1 clinical trial results showed promising safety profiles and anti-tumor activity, particularly in non-small cell lung cancer and thymic squamous cell carcinoma, indicating potential positive implications for the company’s market positioning and stakeholders.
Shanghai Henlius Biotech, Inc. has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation. This development will allow certain unlisted shares of the company to be converted into H shares, which will be listed and traded on the Main Board of the Hong Kong Stock Exchange. This move is expected to enhance the company’s market presence and liquidity, providing more opportunities for investors and potentially strengthening its position in the biopharmaceutical industry.
Shanghai Henlius Biotech, Inc. announced that its subsidiary, Henlius Europe GmbH, received orphan-drug designation from the European Commission for HLX22, a recombinant humanized anti-HER2 monoclonal antibody injection, for the treatment of gastric cancer. This designation, which follows a positive opinion from the European Medicines Agency, highlights the company’s progress in developing HLX22, which is undergoing various clinical trials for different cancer indications. The global market for HER2-targeting monoclonal antibody products was valued at approximately $9.029 billion in 2024, indicating significant market potential for HLX22.